THE ANTI-PLATELET EFFECT OF PRE-TREATMENT WITH CLOPIDOGREL IN PATIENTS UNDERGOING PRIMARY PERCUTANEOUS ANGIOPLASTY FOR ST SEGMENT ELEVATION MYOCARDIAL INFARCTION  by Beigel, Roy et al.
E945
JACC April 5, 2011
Volume 57, Issue 14
  MYOCARDIAL ISCHEMIA AND INFARCTION 
THE ANTI-PLATELET EFFECT OF PRE-TREATMENT WITH CLOPIDOGREL IN PATIENTS UNDERGOING 
PRIMARY PERCUTANEOUS ANGIOPLASTY FOR ST SEGMENT ELEVATION MYOCARDIAL INFARCTION
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-11:15 a.m.
Session Title: Acute Myocardial Infarction -- Antiplatelet Therapies
Abstract Category: 3. Acute Myocardial Infarction—Therapy
Session-Poster Board Number: 1005-313
Authors: Roy Beigel, Paul Fefer, Boris Shenkman, Noam Fink, Elad Asher, Hanoch Hod, Shlomi Matetzky, Sheba Medical Center, Tel Hashomer, Israel
Background:  Pre-treatment with clopidogrel prior to percutaneous intervention (PCI) has been proven effective in various clinical settings. Small 
retrospective studies have suggested clinical benefit for clopidogrel pre-treatment in the setting of primary PCI (PPCI) in patients with ST segment 
elevation myocardial infarction (STEMI). However, the anti platelet effect of pre-treatment with clopidogrel prior to PPCI, during the narrow “door to 
balloon” timeframe, in patients presenting with STEMI has yet to be evaluated.
Methods:  Platelet function tests using light transmitted aggregometry were prospectively assessed in 31 consecutive patients presenting with 
STEMI. All patients were treated with clopidogrel loading (600mg) upon admission. Blood was drawn for ADP induced aggregation prior to clopidogrel 
loading, at PPCI, and 72 hours later. In addition, an ECG (recorded at presentation and after PPCI evaluating ST segment resolution) was assessed as 
a marker for myocardial reperfusion.
Results:  Baseline ADP induced aggregation was 81±7%. The mean clopidogrel to balloon time was 50±18 minutes, during which ADP induced 
aggregation was reduced to 76±10% (P=0.0096). A positive response clopidogrel was defined as > 10% reduction in ADP induced aggregation or < 
70% ADP induced aggregation with 19% and 26% of the patients meeting these definitions respectively. 72 hours later ADP induced aggregation was 
further reduced to 50±18% (P<0.001 to baseline). Early ST segment resolution of >50% upon ECG was associated with achieving lower ADP induced 
aggregation at PPCI (82±6.1 vs. 74±10, P=0.029).
Conclusions:  In patients undergoing PPCI for STEMI clopidogrel pre-treatment was associated with a significant but modest reduction in platelet 
ADP induced aggregation which was associated with somewhat better myocardial reperfusion. This might account for the previously shown clinical 
benefit of clopidogrel pre-treatment in patients undergoing PPCI. The use of newer ADP blockers with a more rapid onset of action and potent effect 
may prove even greater benefit in patients undergoing PPCI.
